"None of these brokers or analysis are worth their fees. Across all of small caps land they put out very basic unthoughtful gibberish and pass it off as analysis... its a joke really.."
To “the masses” 3 patients in a phase 1 may seem very early and tiny number. To people who know the field HG-CT-01 is doing something that isn’t seen/ hasn’t been seen before looks very much like a safe effective CAR-T in FLT3 +ve r/r aml. Though early it looks like the start of something that could rewrite the treatment landscape. And that’s why the market may start putting in those higher highs — because the people who really get it, get it. If you had been here a bit longer I have explained it many many times